Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 280033650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,374.00 | 82.20 | -0.97% |
| CAC 40 | 7,727.93 | 42.55 | -0.55% |
| DAX 40 | 23,344.54 | 257.89 | 1.12% |
| Dow JONES (US) | 41,389.68 | 72.25 | 0.17% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,504.68 | 385.27 | 1.74% |
| NASDAQ | 17,928.84 | 48.89 | -0.27% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,421.25 | 93.36 | 0.76% |
| S&P 500 | 5,674.83 | 11.84 | -0.21% |
| S&P/ASX 200 | 8,157.80 | 80.20 | -0.97% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |